SCHEMBL24499340

SCHEMBL24499340

Cc1ccc(C2(c3ccc(P)cc3)CCCCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.50
ESR2 Q92731 4/20 0.50
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HSD11B1 P28845 4/20 0.44
HSD11B2 P80365 3/20 0.44
ACHE P22303 1/20 0.41
LMNA P02545 2/20 0.41
ALOX12 P18054 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
OPRM1 P35372 1/20 0.38
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PSMB1 P20618 1/20 0.36
PSMB5 P28074 1/20 0.36
PSMB2 P49721 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
POLB P06746 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18403094 0.89 ESR1 (0.60) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL20080439 0.82 ESR1 (0.52) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL9973089 0.80 ALDH1A1 (0.80) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL822829 0.80 ESR1 (0.80) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL12893281 0.80 ESR1 (0.80) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL5452904 0.78 ESR1 (0.48) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL13879208 0.78 ESR1 (0.48) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL21168792 0.78 ESR1 (0.48) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL2534363 0.78 ESR1 (0.48) ESR1ESR2ALDH1A1L3MBTL1HSD11B1
SCHEMBL12306231 0.78 ESR1 (0.48) ESR1ESR2ALDH1A1L3MBTL1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177641-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177641-A1 CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND CROCC, RCSD1, WDR5 ESR1 3744/4885ESR2 2593/4885ALDH1A1 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.